Research led by Amsterdam UMC, across more than 5 years and 1100 patients has demonstrated a strategy for reducing inappropriate IV use by a third, an effect that was sustained across the five-year period.
Senators tell FDA that ‘greater action is needed’ to use manufacturing tech in US supply chains
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
September 19, 2024